Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study

References

• Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) 2019;71:1285–99.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82:19–34.
   PubMed Web of Science ®Google Scholar
• Xie S, Li S, Tian J, Li F. Iguratimod as a new drug for rheumatoid arthritis: current landscape. Front Pharmacol 2020;11:73.
   PubMed Web of Science ®Google Scholar
• Mu R, Li C, Li X, Ke Y, Zhao L, Chen L, et al. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: a nationwide, prospective real-world study. Lancet Reg Health West Pac 2021;10:100128.
   PubMedGoogle Scholar
• Zeng L, He Q, Deng Y, Li Y, Chen J, Yang K, et al. Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials. Front Pharmacol 2023;14:1189142.
   PubMed Web of Science ®Google Scholar
• Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 2001;28:2591–6.
   PubMed Web of Science ®Google Scholar
• Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 2013;191:4969–78.
   PubMed Web of Science ®Google Scholar
• Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, et al. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-kappaB pathway. Sci Rep 2018;8:1933.
   PubMed Web of Science ®Google Scholar
• Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, et al. Identification of iguratimod as an inhibitor of macrophage Migration Inhibitory Factor (MIF) with steroid-sparing potential. J Biol Chem 2016;291:26502–14.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu Q, Song J, Liu H, Miao Y, Yang F, et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediators Inflamm 2015;2015:356040.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 2003;42:1365–71.
   PubMed Web of Science ®Google Scholar
• Wu YX, Sun Y, Ye YP, Zhang P, Guo JC, Huang JM, et al. Iguratimod prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator-activated receptor-gamma. Mol Med Rep 2017;16:8200–8.
   PubMed Web of Science ®Google Scholar
• Kuriyama K, Higuchi C, Tanaka K, Yoshikawa H, Itoh K. A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun 2002;299:903–9.
   PubMed Web of Science ®Google Scholar
• Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010;6:399–405.
   PubMed Web of Science ®Google Scholar
• Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016;374:2563–74.
   PubMed Web of Science ®Google Scholar
• Liu S, Cui Y, Zhang X. Molecular mechanisms and clinical studies of iguratimod for the treatment of ankylosing spondylitis. Clin Rheumatol 2021;40:25–32.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zheng N, Wu R. Is iguratimod effective in refractory axial spondyloarthritis? Scand J Rheumatol 2018;47:518–20.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Tang Y, Rui J, Li J. Clinical observation on treatment of refractory ankylosing spondylitis by Iguratimod. J Jiangsu Univ (Medicine Edition) 2016;26:235–9.
   Google Scholar
• Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703–9.
   PubMed Web of Science ®Google Scholar
• Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249–51.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park YW, Choe JY, Shin K, Kwon SR, Cha JH, et al. Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea. Int J Rheum Dis 2020;23:342–9.
   PubMed Web of Science ®Google Scholar
• Liew JW, Ward MM, Reveille JD, Weisman M, Brown MA, Lee M, et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2020;72:1645–52.
   PubMed Web of Science ®Google Scholar
• Bergman M, Lundholm A. Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis. Rheumatology (Oxford) 2018;57:419–28.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, Mackay F, Mariette Xmarcelli C, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165–78.
   PubMed Web of Science ®Google Scholar
• Ouyang D, Ma YZ, Zou J, Wang YL, Chen Z, Yang YY, et al. Effectiveness and safety of iguratimod monotherapy or combined with methotrexate in treating rheumatoid arthritis: a systematic review and meta-analysis. Front Pharmacol 2022;13:911810.
   PubMed Web of Science ®Google Scholar
• Li Y, Li K, Zhao Z, Wang Y, Jin J, Guo J, et al. Randomised, double-blind, placebo-controlled study of iguratimod in the treatment of active spondyloarthritis. Front Med Lausanne 2021;8:678864.
   PubMed Web of Science ®Google Scholar
• Weber U, Maksymowych WP, Jurik AG, Pfirrmann CW, Rufibach K, Kissling RO, et al. Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 2009;61:893–9.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zheng J, Zhang X, Zeng H, Luo R. Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system. Arthritis Res Ther 2016;18:38.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo Z, Zhan Y, Qu J, Lei X. Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis Research Consortium of Canada scoring system. BMC Musculoskelet Disord 2022;23:654.
   PubMed Web of Science ®Google Scholar
• Zhang P, Yu K, Guo R, Shah S, Morelli JN, Runge VA, et al. Ankylosing spondylitis: correlations between clinical and MRI indices of sacroiliitis activity. Clin Radiol 2015;70:62–6.
   PubMed Web of Science ®Google Scholar
• MacKay JW, Aboelmagd S, Gaffney JK. Correlation between clinical and MRI disease activity scores in axial spondyloarthritis. Clin Rheumatol 2015;34:1633–8.
   PubMed Web of Science ®Google Scholar